• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Progress in Artificial Intelligence >Intravenous drug incompatibilities in the intensive care unit of a tertiary care hospital in India: Are they preventable?
【24h】

Intravenous drug incompatibilities in the intensive care unit of a tertiary care hospital in India: Are they preventable?

机译：印度高等院护理医院密集护理单位的静脉内药物不兼容性：他们可以预防吗？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: The main aim of the study was to identify the physical and chemical incompatibilities among the drugs administered intravenously to patients admitted to the Intensive Care Unit (ICU) of a 1000 bedded hospital. The study also envisaged establishing pharmaceutical guidelines for the administration of incompatible medications. Methods: This prospective cross-sectional study was conducted from January to July 2018 in the ICU after getting approval from the Hospital Ethics Committee. A total of 104 medication charts were collected, and their data were analyzed. Compatibility of the selected drug with a second drug, when given together, was then analyzed using the Micromedex health-care series, Trissel's handbook of injectable drugs, and Manufacturer's product information. The pharmaceutical intervention was performed by preparing. The drug compatibility chart of selected drugs and the same was reported to the study department. Findings: Of 104 medication charts reviewed, 66 charts had incompatibility, accounting for 90 incompatibilities. Incompatibility between two intravenous (IV) bolus drugs constituted 68.8% with pantoprazole and ondansetron (85.4%) being the most frequent combination. Incompatibility between infusion-bolus was found to be 26.6%. Meropenem (infusion) and pantoprazole (bolus) constituted 16.6%. Incompatibility between two infusions in the same IV line was found to be 4.4%. A drug compatibility chart containing 19 selected drugs was prepared and submitted to the study department for their perusal. Conclusion: The current study showed that a significant number of drug incompatibilities occur in hospitalized critically ill patients in our tertiary care hospital. These incompatibilities could generally be prevented by adhering to proper medication administration techniques like flushing the line using compatible fluid or through a multi-lumen catheter or multiple IV access.
机译：目的：该研究的主要目的是识别静脉内施用的药物的物理和化学不相容性，静脉内施用1000卧床医院的重症监护股（ICU）。该研究还设想建立药物指南的施用不相容的药物。方法：在医院伦理委员会获得批准后，ICU于2018年1月至2018年1月至7月进行了这项前瞻性横断面研究。收集了总共104个药物图表，分析了他们的数据。使用MicroMedex保健系列，Trissel的可注射药物手册和制造商的产品信息，将所选药物与第二种药物的相容性进行分析。通过制备进行药物干预。研究部门报告了所选药物和相同的药物相容图。结果：审查了104个药物图表，66张图表具有不相容，占90个不相容性。两个静脉内（IV）推注药物之间的不相容性68.8％，泮托拉唑和ondansetron（85.4％）是最常见的组合。发现输注推注的不相容性是26.6％。梅洛宁（输注）和泮托拉唑（推注）构成16.6％。发现同一IV线中的两种输注之间的不相容性为4.4％。制备含有19种药物的药物兼容性图表，并提交给研究部门的Perusal。结论：目前的研究表明，在我们的第三级护理医院住院治疗患者的住院治疗患者的大量药物不相容性。通常可以通过粘附到使用兼容的流体或通过多腔导管或多次IV接入等冲洗线的适当药物管理技术来防止这些不相容性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号